Discontinued Operations (Details) (USD $)	3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		1 Months Ended	3 Months Ended	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014 Discontinued operations	Jun. 30, 2013 Discontinued operations	Jun. 30, 2014 Discontinued operations	Jun. 30, 2013 Discontinued operations	May 31, 2014 Discontinued operations Special Long-Term Retention and Incentive Cash Awards Program	Mar. 31, 2014 Discontinued operations Special Long-Term Retention and Incentive Cash Awards Program	Dec. 31, 2011 Discontinued operations Special Long-Term Retention and Incentive Cash Awards Program
Components of research and drug development operations presented on condensed consolidated statements of operations
Net revenues	$ 2,184,000	$ 5,000	$ 3,129,000	$ 27,000
Loss from discontinued operations	(43,413,000)	(34,888,000)	(94,934,000)	(61,502,000)
Reimbursement of research and development costs from discontinued operations from collaborative arrangements					22,000	2,100,000	100,000	3,900,000
Timeframe for achievement of performance conditions											6 years
Stock-based compensation expense	7,747,000	7,162,000	21,281,000	13,257,000	4,152,000	4,994,000	11,629,000	9,355,000
Compensation expenses related to cash bonus recognized in current year given sufficient performance conditions achieved										9,100,000
Total cash bonus paid									$ 9,500,000